Compare iShares iBoxx $ Inv Grade Corporate Bond ETF (LQD) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares iBoxx $ Inv Grade Corporate Bond ETF vs Revvity Inc — how do they compare? iShares iBoxx $ Inv Grade Corporate Bond ETF trades at $106.68, while Revvity Inc trades at $110.67 (market cap $12.33B). The key difference: Revvity Inc pays a 0.25% dividend while iShares iBoxx $ Inv Grade Corporate Bond ETF pays none, and Revvity Inc is trading nearer its 52-week high, iShares iBoxx $ Inv Grade Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| LQD | RVTY | |
|---|---|---|
52-Week High | $112.91 | $117.75 |
52-Week Low | $106.85 | $82.26 |
Market Cap | — | $12.33B |
Sector | — | Technology |
Enterprise Value | — | $14.82B |
Dividend Yield | — | 0.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LQD trades at $107.15, down 0.38% on the day, with technical indicators showing a bearish trend from moving averages while oscillators are neutral. The ETF maintains a consistent dividend schedule, with recent payments around $0.40-0.42 per share. Market sentiment is mixed amid Federal Reserve uncertainty and shifting bond flows.
The outlook for LQD hinges on interest rate direction and corporate bond demand. Opportunities exist for income-focused investors seeking investment-grade exposure, but risks include potential Fed rate hikes and economic volatility that could pressure bond prices. Current technical weakness suggests cautious near-term positioning.
RVTY trades at $106.44, down 3.37% today, with a bullish technical outlook despite near-term weakness. The company maintains stable revenue around $2.9B with consistent earnings beats, though valuation multiples appear elevated with a P/E of 51. Recent AI product launches and FDA clearances demonstrate innovation in life sciences and diagnostics. Analyst consensus remains positive with a $111.43 price target and no sell ratings among 29 covering firms.
The stock presents a growth opportunity with strong analyst support and technological innovation, but faces risks from margin pressure and China market exposure. Current levels near support at $105 offer potential entry, though the high P/E requires sustained earnings growth to justify valuation. Upcoming Q2 earnings on August 4, 2026 will be critical for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares iBoxx $ Inv Grade Corporate Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in fixed income securities of the types included in the underlying index that the advisor believes will help the fund track the underlying index. The underlying index is designed to provide a broad representation of the US dollar-denominated liquid investment-grade corporate bond market.
Read more on LQD →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
